Willow Springs Distilling Company

WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2023 RESULTS

Retrieved on: 
Friday, May 12, 2023
Food, Bank statement, Sandhill, Active ingredient, CBG, The Company, SEDAR, Drug discovery, Protein engineering, TSX, Growth, WLLW, Biocatalysis, M3, Willow Springs Distilling Company, Willow, Fine chemical, Renewable energy, Cannabigerol

Willow's unaudited consolidated interim financial statements and related management's discussion and analysis for the quarter ended March 31, 2023 are available on SEDAR at www.sedar.com .

Key Points: 
  • Willow's unaudited consolidated interim financial statements and related management's discussion and analysis for the quarter ended March 31, 2023 are available on SEDAR at www.sedar.com .
  • On February 22, 2023, Willow announced the appointment of Jim Lalonde, Ph.D. as its newest independent member of the Company's Board of Directors, effective February 21, 2023.
  • Willow ended the quarter with strong liquidity, including approximately $10.5 million of cash as of March 31, 2023, with the Company's approved annual budget expected to be fully funded for 2023.
  • The Company reported revenue of $274,000 for the quarter compared to nil revenue for the first quarter of 2022.

WILLOW ANNOUNCES ROLLOUT OF BioOxi PLATFORM PROVIDING VALUABLE AND EXPEDITED BIOCONVERSION-ENABLED CHEMICAL MANUFACTURING

Retrieved on: 
Wednesday, April 12, 2023
Ursodeoxycholic acid, Willow Springs Distilling Company, Biotechnology, Fermentation, Adsorption/Bio-oxidation process, Master service agreement, Polyphenol, UDCA, Steroid, TSX, WLLW, Fine chemical, Willow

Through the Company's legacy expertise, Willow is now able to offer commercial partners both cost-effective production of ingredients through biosynthesis, and now through BioOxi, bioconversion-enabled chemical manufacturing of ingredients from defined intermediates with the benefit of removing multiple chemical steps and significantly reducing cost and resources.

Key Points: 
  • Through the Company's legacy expertise, Willow is now able to offer commercial partners both cost-effective production of ingredients through biosynthesis, and now through BioOxi, bioconversion-enabled chemical manufacturing of ingredients from defined intermediates with the benefit of removing multiple chemical steps and significantly reducing cost and resources.
  • "We see this new platform as posing a powerful, clean and cost-effective solution to our prospective partners' chemical manufacturing challenges that is highly complementary to our existing strain engineering and precision fermentation business.
  • Based on our prior success in utilizing BioOxi to support our partners we believe it will lead to additional commercial agreements going forward."
  • The launch of BioOxi broadens Willow's addressable total market opportunity and provides nearer-term revenue generation for BioOxi-related projects.

WILLOW BIOSCIENCES ANNOUNCES CHANGES TO BOARD AND MANAGEMENT

Retrieved on: 
Tuesday, March 28, 2023
Precigen, Xavier University, LLP, Lead, Codexis, University, Genetic engineering, Willow Springs Distilling Company, Army Science Board, PwC, Barr Pharmaceuticals, AGM, Certified Public Accountant, CBG, Development, Amyris, Partner, Chris, TSX, Growth, CFO, Research, WLLW, Compensated emancipation, Management, Willow

Since joining Willow, Dr. Savile has led the development of the technology platform, building of the operational capabilities, and expansion of the internal portfolio and external partnerships.

Key Points: 
  • Since joining Willow, Dr. Savile has led the development of the technology platform, building of the operational capabilities, and expansion of the internal portfolio and external partnerships.
  • Prior to joining Willow, Dr. Savile worked in senior leadership roles at Intrexon Corporation, a biotechnology company, and Codexis, Inc., a protein engineering company.
  • "Chris' extensive scientific knowledge and business development experience will be invaluable to Willow in its next phase of growth," said Trevor Peters, Chairman of the Board.
  • "Willow is grateful to Dr. Seufer-Wasserthal's vision and talent," said Trevor Peters, Chairman of the Board of the Company.

WILLOW BIOSCIENCES PROVIDES CBG UPDATE

Retrieved on: 
Wednesday, August 31, 2022
COVID-19, AB, AMRI, Food, Willow Springs Distilling Company, Research, Hand, View, Government, Protein, DSP, Generally recognized as safe, Technology transfer, Interim, Risk, WLLW, TSX, Patent, Willow Garage, Multimedia, MSA, CDMO, Company, Certification, Contract, News, Failure, Fermentation, GRAS, Intellectual property, Cannabinoid, Industry, Health, Forward-looking statement, CBG, Fine chemical, Willow

CALGARY, AB and MOUNTAIN VIEW, Calif, Aug. 31, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX:WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to provide an update on cannabigerol ("CBG"), the Company's first commercialized functional ingredient in its portfolio.

Key Points: 
  • CALGARY, AB and MOUNTAIN VIEW, Calif, Aug. 31, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX:WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to provide an update on cannabigerol ("CBG"), the Company's first commercialized functional ingredient in its portfolio.
  • As the market for biosynthetically produced CBG continues to develop, Willow will be in a strong position to deliver commercial scale volumes.
  • When the regulatory environment permits, Willow is also well-positioned to develop additional cannabinoids beyond CBG.
  • Willow previously announced that it had successfully completed the initial toxicological assessment for Generally Recognized as Safe ("GRAS") for its FutureGrown CBG product.

WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT

Retrieved on: 
Tuesday, May 31, 2022
WLLW, API, Company, Food, News, Multimedia, View, Government, COVID-19, Failure, TSX, AB, Research, Active ingredient, Industry, Partnership, Intellectual property, Forward-looking statement, Risk, Counterparty, Willow Springs Distilling Company, Hand, Fermentation, Fine chemical, Risk management, Willow

"This is a significant step forward in the evolution of Willow's business", said Trevor Peters, Willow's President and Chief Executive Officer.

Key Points: 
  • "This is a significant step forward in the evolution of Willow's business", said Trevor Peters, Willow's President and Chief Executive Officer.
  • As Willow continues to expand its capabilities and add new partnerships, Willow is on a path to becoming the premier name in biobased manufacturing."
  • The project consists of research & development and commercialization phases, with revenue coming from both research fees and milestone payments.
  • Willow develops and produces high-purity ingredients for the personal care, food and beverage, and pharmaceutical markets.

WILLOW BIOSCIENCES ANNOUNCES EXPANSION OF ITS FERMENTATION MANUFACTURING NETWORK AND PROGRESS ON ITS CBG GRAS DETERMINATION

Retrieved on: 
Wednesday, May 11, 2022
WLLW, Contract, Company, GRAS, Plant, Certification, Food, News, Multimedia, CDMO, View, Government, Cannabinoid, COVID-19, Failure, TSX, Research, Industry, Carbon, Partnership, Biotechnology, Intellectual property, Forward-looking statement, Risk, Willow Springs Distilling Company, MSA, Hand, Fermentation, Fine chemical, Risk management, Willow, BC

This new CDMO partnership allows Willow to accommodate new programs, both internal and partnered, in addition to its cannabinoid portfolio.

Key Points: 
  • This new CDMO partnership allows Willow to accommodate new programs, both internal and partnered, in addition to its cannabinoid portfolio.
  • Willow has successfully completedthe Stage 1toxicological assessment of its FutureGrown CBG product for oral product applications, an important milestone for biosynthetically produced cannabinoids.
  • The assessment concluded that FutureGrownTM CBG was non-mutagenic, non-clastogenic, non-genotoxic, which, is the first step toward concluding Willow's FutureGrown CBG as GRAS in the United States.
  • Willow produces its FutureGrown CBG through precision fermentation, drastically reducing production time and carbon footprint when compared to traditionally grown cannabis extracts.

WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST

Retrieved on: 
Monday, January 31, 2022
Webcast, Food, View, Microsoft PowerPoint, Biotechnology, WLLW, Cannabinoid, TSX, Company, Risk, Q&A, News, Willow Springs Distilling Company, Multimedia, B2C, Fine chemical, Willow, BC

VANCOUVER, BC, Jan. 31, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company that manufactures pure, consistent and sustainable cannabinoids via yeast biosynthesis, today announced that it will host a webcast investor presentation on Thursday, February 3rd at 2:00 PM EST.

Key Points: 
  • VANCOUVER, BC, Jan. 31, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company that manufactures pure, consistent and sustainable cannabinoids via yeast biosynthesis, today announced that it will host a webcast investor presentation on Thursday, February 3rd at 2:00 PM EST.
  • During the webcast, Willow's President and Chief Executive Officer Trevor Peters will provide a presentation through a PowerPoint discussion that will cover key areas of Willow's business.
  • After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.
  • To listen to the webcast or to ask questions during the live event, please pre-register at the following link:
    An archived version of the webcast and presentation will be available on the Company's website, www.willowbio.com/#investors.